Pharmgate Animal Health has introduced Deracin (chlortetracycline), a generic chlortetracycline product for effective and economical control of shipping fever and anaplasmosis, two of the mostly costly and challenging diseases in the cattle industry.
“We’re pleased to offer cattle producers an economical, easy-to-use solution for shipping fever and anaplasmosis,” said Colin Gray, president and chief executive officer of Pharmgate Animal Health. “Deracin gives producers and veterinarians a choice in products without the need to change treatment protocols or wonder if it will work.”
Deracin is broad spectrum and effective against both Gram-positive and Gram-negative organisms. It is readily absorbed so it quickly reaches effective blood and lung concentrations. Deracin has combination clearances to be fed with lasalocid (Bovatec) or decoqinate (Deccox). It can be top dressed in cattle feeds or fed to cattle on pasture with bluebird free-choice mineral formulas, Pharmgate said.
Deracin is the newest addition to Pharmgate’s growing line of animal health solutions, including feed- and water-soluble medications for multiple species, as well as swine vaccines for protection against respiratory, reproductive and enteric diseases. Pharmgate’s parent company, Jinhe Biotechnology Co., is the world leader in the production of chlortetracycline, which is the active ingredient in Deracin.
“Being the basic manufacturer gives us control over this product from start to finish, allowing us to deliver a product of superior quality,” Gray said. “Our customers can be confident they are getting value and trusted performance when they use Deracin to restore cattle health and well-being.”
Deracin is a veterinary feed directive (VFD) drug to be used by or on the order of a licensed veterinarian.
Pharmgate Animal Health is headquartered in Wilmington, N.C. and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production.
The company’s pharmaceutical production facilities are located in Omaha, Neb.; vaccine research and manufacturing operations are based in St. Paul, Minn.